Previous Page  4 / 26 Next Page
Information
Show Menu
Previous Page 4 / 26 Next Page
Page Background

Clare Tempany:

I agree, and it has

changed a lot since I began in this

career. It’s been at least 20 years

that I’ve been doing this kind of

research. It was much easier 20

years ago than it is today for sure. 20

years ago, it was simple to have a

relationship with someone who was

interested in your science, who

wanted to fund you, invite you to

give a talk, speak to a group, or go to

a meeting. All of these things were

much more encouraged.

Nowadays, there is this very big

sensitivity about confidentiality of

data,

intellectual

property,

proprietary rights, and then of

course, in the US, the concern of

Influencing or changing the doctor

because of undue influence.

Particularly in the state I live in,

Massachusetts, we have a Sunshine

Law, by which I cannot go to a

reception or a party given by anyone

in the industry without declaring,

writing, and letting everyone know.

Of course, I have to acknowledge the

support all the time, which we do.

It’s become very difficult with

strange relationships.

Absolutely, you are correct. This led

to this bottleneck in working

through agreements, contracts, any

form of negotiation with the

partners in industry and academia

doing research projects together.

Both sides now have legal teams

who are very careful about the

wording of the contracts. The

leading problem is which legal team

is the dominating one. Usually, they

are jockeying a little bit. Then usually

a standard is set. The hospital says:

”Ok, this is the template we use. This

is the agreement.” Then the industry

eventually says yes if they are

motivated enough.

A lot of the time the problem with

the bottleneck is that it causes

people to question the motivation.

Do I really want to do this or do I

not? They say, “Is it worth this effort

or this fight?” So then they sort of

say, “No, it’s not worth it. I’ll go

somewhere else.”

Ralph:

What are the criteria to

decide if something is worth it or

not? Is it money?

Clare:

It is everything. Does the

CVPR Daily: Thursday

Prof. Clare Tempany

4

MICCAI Daily: Thursday

It was much easier 20 years ago

than it is today for sure

Ralph Anzarouth:

You have been for a long time

already at the key junction of these three areas:

academia, medicine, and industry. During these

past few days I’ve been hearing so often the idea

of a “bottleneck” in the relations between these

three worlds. Everyone says it will improve. What

are the problems and what are the domains in

which it should improve?